Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites
| Autor: | J L, McGuire, A, Phillips, D W, Hahn, E L, Tolman, S, Flor, M E, Kafrissen |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject Metabolite Levonorgestrel Pharmacology chemistry.chemical_compound Health services Pharmacokinetics Internal medicine Oximes medicine Animals Humans Norelgestromin Biotransformation media_common Molecular Structure Biologic response business.industry Norgestrel Obstetrics and Gynecology Norgestimate Drug Combinations Endocrinology chemistry Female business Contraceptives Oral medicine.drug |
| Zdroj: | American Journal of Obstetrics and Gynecology. 163:2127-2131 |
| ISSN: | 0002-9378 |
| Popis: | Biotransformation, pharmacologic, and pharmacokinetic studies of norgestimate and its metabolites indicate that 17-deacetyl norgestimate, along with the parent drug, contributes to the biologic response. The postulated metabolic pathway, which is based on the identification of urinary products had indicated that three metabolites of norgestimate, 17-deacetyl norgestimate, 3-keto norgestimate, and levonorgestrel, might participate in the response. The pharmacologic evaluation of these metabolites demonstrates that only 17-deacetyl norgestimate has a pharmacologic profile consistent with that of norgestimate, and significant concentrations of this metabolite have been measured in the serum of women after the administration of norgestimate. These studies indicate that 17-deacetyl norgestimate contributes to the pharmacologic response to norgestimate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|